Zepbound

Quote










































It's absolutely adorable how you guys think that Kowa, a class B(or C) pharma company, is going to get a class A drug like Zepbound. You realize there are other companies that already work with Lily(syneos) that are far more likely to get this, or even mounjaro than we are. That is even putting aside that Lily has it's own sales force that should easily be able to carry both of these drugs. Frankly neither need a sales force because the public and providers already know them by name. Even though my mind wanders, I'm a realist. Try looking at other Lily diabetes and migraine meds. That is most likely where we will be hanging our hats.
 






anonymous said:
It's absolutely adorable how you guys think that Kowa, a class B(or C) pharma company, is going to get a class A drug like Zepbound. You realize there are other companies that already work with Lily(syneos) that are far more likely to get this, or even mounjaro than we are. That is even putting aside that Lily has it's own sales force that should easily be able to carry both of these drugs. Frankly neither need a sales force because the public and providers already know them by name. Even though my mind wanders, I'm a realist. Try looking at other Lily diabetes and migraine meds. That is most likely where we will be hanging our hats.
Click to expand...
Why don’t you all just shut up and wait and see what happens?
 










































Zepbound is an interesting guess fits the Indy NSM and not sure why they would take Kowa on considering what a great job was done with Seglentis and they helped launch Livalo and we hated them, but anything is possible, and Jeff would probably take less to use Kowa than Syneos would have to pay average salaried reps in the industry so there is an upside, lower costs and if you don't help then they cancel.
 






anonymous said:
Zepbound is an interesting guess fits the Indy NSM and not sure why they would take Kowa on considering what a great job was done with Seglentis and they helped launch Livalo and we hated them, but anything is possible, and Jeff would probably take less to use Kowa than Syneos would have to pay average salaried reps in the industry so there is an upside, lower costs and if you don't help then they cancel.
Click to expand...

It is not Zepbound.
 












anonymous said:
so tell us what it IS!
:rolleyes::rolleyes::rolleyes:
Click to expand...

Reps don’t understand the Zepbound potential. We are talking the biggest drug in pharmaceutical history beating statins when they all hit the market. This is a $250-$500 billion annual industry in a few years. All doctors talk about it and know it. The studies keep coming out showing how much benefit this drug is. Kowa won’t launch it. They play with smaller drug.
 






Seriously, why would Lilly sign a co-promote agree with Kowa promoting "the biggest drug in pharmaceutical history beating statins" ? Great Leadership? I think not. So give me a few good reasons why you think this may happen?
 






Top Bottom
Back
Quote